Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Mar 30, 2026
- Accession no.
- 0001628280-26-022135
- Filed
- Mar 30, 2026
- Trade date
- Mar 26, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $106.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Common Stock | MOption exerciseAcquired | +550 | $2.39 | +$1,314.5 | 22,029 | Direct | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −550 | $25.55F2 | −$14,052.5 | 21,479 | Direct | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −1,357 | $25.55F2 | −$34,671.35 | 50,209 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −1,153 | $25.55F2 | −$29,459.15 | 42,673 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −278 | $25.55F2 | −$7,102.9 | 3,058 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −278 | $25.55F2 | −$7,102.9 | 3,058 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −278 | $25.55F2 | −$7,102.9 | 3,058 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −278 | $25.55F2 | −$7,102.9 | 3,058 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Common Stock | MOption exerciseDisposed | −550 | $0.00 | $0 | 13,732 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $25.050 to $25.955, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.